An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout

Current Opinion in Rheumatology

Volumn 26, Issue 2, 2014, Pages 152-161

  Nuki, George ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

AGREE II; American College of Rheumatology; clinical practice guidelines; gout; hyperuricaemia

Indexed keywords

ARTHRITIS, GOUTY; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84894103028     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000034     Document Type: Review

References (37)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63:3136-3141
2. Richette P, Bardin T. Gout. Lancet 2010; 375:318-328
3. Langley P, Nuki G, Forsythe A. Pain, health-related quality of life, and health status in gout in Europe. Ann Rheum Dis 2012; 71 (Suppl 3):445
4. Khanna P, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes 2012; 10:117-228
5. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991; 34:141-145
6. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008; 67:1310-1316
7. Pineda C, Amezcula-Guerra LM, Solano C, et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: An ultrasound controlled study. Arthritis Res Ther 2011; 13:R4
8. Nuki G. Treatment of crystal arthropathy: History and advances. Rheum Dis Clin North Am 2006; 32:333-357
9. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1301-1311
10. Roemjinders AC, Gorter KJ. Dutch general practitioners gout guidelines. Ned Tijd Genees 2002; 146:309-313
11. www.prodigy.nhs.uk/guidance.asp?gt=Gout. Prodigy Guidance-Gout. 2004
12. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-1324
13. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46:1372-1374
14. Nakajima H, Matsuzawa Y. Introduction of the new guideline for the management of hyperuricemiaand gout with special reference to its policy [in Japanese]. Nippon Rinsho-Japanese J Clin Med 2003; 61 (Suppl 1):442-449
15. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014; 73:328-335. doi: 10.1136/annrheumdis-2013- 203325
16. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout : Is the incidence increasing? J Rheumatol 2002; 29:2403-2406
17. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years in a managed care population. J Rheumatol 2004; 31:1582-1587
18. Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006; 33:104-109
19. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81:925-934
20. Singh JA, Hodges JS, Toscano JP, et al. Quality of care in the US needs improvement. Arthritis Rheum 2007; 57:822-829
21. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: Prevalence, comorbidities and management in General Practice 2000-2005
22. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11:R46
23. Doherty M, Jansen TL, Nuki G, et al. Gout: Why is this curable disease so seldom cured? Ann Rheum Dis 2012; 71:1765-1770
24. Khanna D, Fitzgerald JD, Khanna PH, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64:1431-1446
25. Khanna D, Khanna PH, Fitzgerald JD, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012; 64:1447-1461
26. Bardin T, Richette P. New ACR gout guidelines hold some surprises. Nat Rev Rheumatol 2013; 9:9-11
27. Institute of Medicine. Clinical practice guidelines we can trust. Washington, DC: National Academics Press; 2011
28. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999; 281:1900-1905
29. Brouwers MC, Kho ME, Browman GR, et al. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010; 182:E839-E842
30. Qaseem A, Forland F, Macbeth F, et al. Guidelines international network: Toward international standards for clinical practice guidelines. Ann Intern Med 2012; 156:525-531
31. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15:981-1000
32. Brook R. The RAND/UCLA Appropriateness Method. In: McCormick KA, Moore SR, Siegel RA, editors. Methodology perspectives: AHCPR no. 95-0009. Rockville, Maryland: Public Health Service; 1994. pp. 59-70
33. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009; 301:831-841
34. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: Proof of concept observational study. Ann Rheum Dis 2013; 72:826-830
35. Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ 2013. [Epub ahead of print] Health economic study showing that febuxostat only becomes cost-effective when used as a second-line ULT in the setting of the UK National Health Service
36. NICE technology appraisal guidance 291. Pegloticase for treating severe debilitating chronic tophaceous gout. June 2013. guidance.nice.org.uk/ ta291 The NICE case for not recommending the use of pegloticase as being insufficiently cost-effective despite FDA and EMA regulatory approval
37. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: A qualitative study. Ann Rheum Dis 2012; 71:1490-1495